nach oben

Arthritis Research & Therapy

Erschienen in:

01.10.2001 | Commentary

Persistent Chlamydiae and chronic arthritis

verfasst von: Cheryl Villareal, Judith A Whittum-Hudson, Alan P Hudson

Erschienen in: Arthritis Research & Therapy | Ausgabe 1/2001

Einloggen, um Zugang zu erhalten

Abstract

Urogenital infection with Chlamydia trachomatis can lead to development of an acute inflammatory arthritis, and this acute disease becomes chronic in some individuals. Research indicates that the organism is present in synovial tissue of patients with chronic disease in a persistent, rather than an actively growing, form. Importantly, metabolic and other characteristics of persistent Chlamydia differ from those of actively growing bacteria. Other studies suggest that Chlamydia pneumoniae can be found in a persistent state in the synovium and that it too may be involved in joint pathogenesis. These and other observations suggest a more complex role for the Chlamydiae in joint disease than previously recognized. This realization should engender a realignment of thinking among clinicians and researchers concerning both mechanisms of chlamydial pathogenesis in the synovium and design of new treatments for the disease.

Schachter J: Infection and disease epidemiology. In Chlamydia: Intracellular Biology, Pathogenesis, and Immunity. Edited by Stephens RS. Washington DC: American Society for Microbiology Press;. 1999, 139-169.

Inman RD, Whittum-Hudson JA, Schumacher HR, Hudson AP: Chlamydia-associated arthritis. Curr Opin Rheumatol. 2000, 12: 254-262. 10.1097/00002281-200007000-00004.PubMedCrossRef

Hackstadt T: Cell biology. In Chlamydia: Intracellular Biology, Pathogenesis, and Immunity. Edited by Stephens RS. Washing-ton DC: American Society for Microbiology Press;. 1999, 101-138.

Beatty WL, Morrison RP, Byrne GI: Persistent Chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev. 1994, 58: 686-699.PubMedPubMedCentral

Moulder JW: Interaction of Chlamydiae and host cells in vitro. Microbiol Rev. 1991, 55: 143-190.PubMedPubMedCentral

Köhler L, Nettelnbreker E, Hudson AP, Ott N, Gérard HC, Brani-gan PJ, Schumacher HR, Drommer J, Zeidler H: Ultrastructural and molecular analysis of the persistence of Chlamydia trachomatis (serovar K) in human monocytes. Microb Pathogen. 1997, 22: 133-142. 10.1006/mpat.1996.0103.CrossRef

Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, Smith P, Schachter J: Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992, 14: 178-182.PubMedCrossRef

Byrne GI, Ouellette SP, Wang Z, Rao JP, Lu L, Beatty WL, Hudson AP: Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of Hep-2 cells. Infect Immun. 2001, 69: 5423-5429. 10.1128/IAI.69.9.5423-5429.2001.PubMedPubMedCentralCrossRef

Beutler AM, Whittum-Hudson JA, Nanagara R, Schumacher HR, Hudson AP: Intracellular location of inapparently-infecting Chlamydia in synovial tissue from patients with Reiter's syndrome. Immunol Res. 1994, 13: 163-171.PubMedCrossRef

10.

Gérard HC, Branigan PJ, Schumacher HR, Hudson AP: Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. J Rheumatol. 1998, 25: 734-742.PubMed

11.

Jones ML, Hill Gaston JS, Pearce JH: Induction of abnormal Chlamydia trachomatis by exposure to interferon-γ or amino acid deprivation and comparative antigenic analysis. Microb Pathogen. 2001, 30: 299-309. 10.1006/mpat.2001.0433.CrossRef

12.

Gérard HC, Krauβe-Opatz B, Rudy D, Rao JP, Zeidler H, Schu-macher HR, Whittum-Hudson JA, Köhler L, Hudson AP: Expression of Chlamydia trachomatis genes required for DNA synthesis and cell division in active vs. persistent infection. Mol Microbiol. 2001, 41: 731-741. 10.1046/j.1365-2958.2001.02550.x.PubMedCrossRef

13.

Schumacher HR: Chlamydia-associated arthritis. Isr Med Assoc J. 2000, 2: 532-535.PubMed

14.

Hammerschlag MR, Golden NH, Oh MK, Gelling M, Sturdevant M, Brown PR, Aras Z, Neuhoff S, Dumornay W, Roblin PM: Single dose of azithromycin for the treatment of genital chlamydial infections in adolescents. J Pediatr. 1993, 122: 961-965.PubMedCrossRef

15.

Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H: Double-blind, placebo-controlled study of three month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum. 1991, 34: 6-14.PubMedCrossRef

16.

Sieper J, Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Hiepe F, Alten R, Keitel W, Groh A, Uksila J, Eggens U, Granfors K, Braun J: No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multi-center, double-blind, randomized, placebo-controlled study. Arthritis Rheum. 1999, 42: 1386-1396. 10.1002/1529-0131(199907)42:7<1386::AID-ANR12>3.0.CO;2-E.PubMedCrossRef

17.

Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, Solbach W, Maass M: Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation. 2001, 103: 351-356.PubMedCrossRef

18.

Kutlin A, Roblin PM, Hammerschlag MR: In vitro activities of azithromycin and orofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother. 1999, 43: 2268-2272.PubMedPubMedCentral

19.

Dreses-Werringloer U, Padubrin I, Jürgens-Saathoff B, Hudson AP, Zeidler H, Köhler L: Persistence of Chlamydia trachomatis is induced by ciprofloxacin and orofloxacin treatment in vitro. Antimicrob Agent Chemother. 2000, 44: 3288-3297. 10.1128/AAC.44.12.3288-3297.2000.CrossRef

20.

Kempsell KE, Cox CJ, Hurle M, Wong A, Wilkie S, Zanders ED, Gaston JS, Crowe JS: Reverse transcription-PCR of bacterial rRNA for detection and characterization of bacterial species in arthritis synovial tissue. Infect Immun. 2000, 68: 6012-6026. 10.1128/IAI.68.10.6012-6026.2000.PubMedPubMedCentralCrossRef

21.

Wilkinson NZ, Kingsley GH, Jones HW, Sieper J, Braun J, Ward ME: Detection of DNA from a range of bacterial species in the joints of patients with a variety of arthritides using a nested, broad-range polymerase chain reaction. Rheumatology. 1999, 38: 260-266. 10.1093/rheumatology/38.3.260.PubMedCrossRef

22.

Gérard HC, Wang Z, Wang GF, El-Gabalawi H, Goldbach-Mansky R, Li Y, Majeed W, Zhang H, Ngai N, Hudson AP, Schu-macher HR: Chromosomal DNA from a variety of bacterial species is present in synovial tissue in patients with various forms of arthritis. Arthritis Rheum. 2001, 44: 1689-1697. 10.1002/1529-0131(200107)44:7<1689::AID-ART293>3.0.CO;2-K.PubMedCrossRef

23.

Beaudreuil J, Hayem G, Meyer O, Khan MF: Reactive arthritis ascribed to Chlamydia pneumoniae . Rev Rhum. 1995, 3: 222-224.

24.

Schumacher HR, Gérard HC, Arayssi TK, Pando JA, Branigan PJ, Saaibi DL, Hudson AP: Chlamydia pneumoniae is present in synovial tissue of arthritis patients with lower prevalence than that of C. trachomatis. Arthritis Rheum. 1999, 42: 1889-1893. 10.1002/1529-0131(199909)42:9<1889::AID-ANR13>3.0.CO;2-W.PubMedCrossRef

25.

Hannu T, Puolakkainen M, Leirisalo-Repo M: Chlamydia pneumoniae as a triggering agent in reactive arthritis. Rheumatology. 1999, 38: 411-414. 10.1093/rheumatology/38.5.411.PubMedCrossRef

26.

Gérard HC, Schumacher HR, El-Gabalawy H, Goldbach-Mansky R, Hudson AP: Chlamydia pneumoniae infecting the human synovium are viable and metabolically active. Microb Pathogen. 2000, 29: 17-24. 10.1006/mpat.2000.0360.CrossRef

27.

Saikku P: Chlamydia pneumoniae B clinical spectrum. In Chlamydial Infection. Proceedings of the International Chlamydia Symposium, San Francisco. Edited by Stephens RS, Byrne GI, Christiansen G, Clarke IN, Grayston JT, Rank RG, Ridgway GL, Saikku P, Schachter J, Stamm WE. Napa, CA, USA,. 1998, 145-154.

28.

Cates W, Wasserheit JH: Genital chlamydial infections: epidemiology and reproductive consequences. Am J Obstet Gynecol. 1991, 164: 1771-1781.PubMedCrossRef

29.

Anttila R, Saikku P, Koskela P, Bloigu A, Dillner J, Ikaheimo I, Jellum E, Lehtinen M, Lenner P, Hakulinen T, Narvanen A, Pukkala E, Thoresen S, Youngman L, Paavonen J: Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. J Am Med Assoc. 2001, 285: 47-51. 10.1001/jama.285.1.47.CrossRef

30.

Mahony JB, Coombes BK: Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role?. FEMS Microbiol Lett. 2001, 197: 1-9. 10.1016/S0378-1097(01)00083-0.PubMedCrossRef

31.

Sriram S, Stratton CW, Yao SY, Tharp A, Ding L, Bannon JD, Mitchell WM: Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol. 1999, 46: 6-14. 10.1002/1531-8249(199907)46:1<6::AID-ANA4>3.3.CO;2-D.PubMedCrossRef

32.

Lenz DC, Lu L, Conant SB, Wolf NA, Gérard HC, Whittum-Hudson JA, Hudson AP, Swanborg RH: A Chlamydia pneumoniae-specific peptide induces experimental autoimmune encephalomyelitis in rats. J Immunol. 2001, 167: 1803-1808.PubMedCrossRef

33.

Balin BJ, Gérard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP: Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol. 1998, 187: 23-42. 10.1007/s004300050071.PubMedCrossRef

34.

Weyand CM, Goronzy JJ: The molecular basis of rheumatoid arthritis. J Mol Med. 1997, 75: 772-785. 10.1007/s001090050167.PubMedCrossRef

35.

Ebringer A, Wilson C, Tiwana H: Is rheumatoid arthritis a form of reactive arthritis?. J Rheumatol. 2000, 27: 559-563.PubMed

36.

O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, Eckhoff PJ, Klassen LW, Chuchill M, Doud D, Weaver A, Moore GF: Treatment of early seropositive rheumatoid arthritis with minocycline. Arthritis Rheum. 1999, 42: 1691-1695. 10.1002/1529-0131(199908)42:8<1691::AID-ANR18>3.0.CO;2-S.PubMedCrossRef

37.

Ford DK, Schulzer M: Synovial lymphocytes indicate 'bacterial' agents may cause some cases of rheumatoid arthritis. J Rheumatol. 1994, 21: 1447-1449.PubMed

38.

Pando JA, Yarboro C, El Lallan A, Saaibi D, Branigan PJ, Gérard HC, Meng ZF, Hudson AP, Gourley MF, Kanik KS, Villalba L, Klippel JH, Schumacher HR: Prevalence of Chlamydia trachomatis by PCR in the synovium of patients with early rheumatoid arthritis [abstract]. Arthritis Rheum. 1995, 38: S287-

Titel: Persistent Chlamydiae and chronic arthritis
verfasst von: Cheryl Villareal
Judith A Whittum-Hudson
Alan P Hudson
Publikationsdatum: 01.10.2001
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 1/2001
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar382

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2001

Central tolerance requires a Bim

Graves' disease immunoglobulins induce expression of T-cell chemoattractants in fibroblasts

Lyme disease and current aspects of immunization

GILT influences antigen processing

Anti-tumour necrosis factor (TNF)-α therapy (etanercept)